Synergistic Activation of PKA

Selective Activation of Protein Kinase A Isozymes I or II Taking Advantage of Synergistic Pairs of cAMP Analogs with Opposite Site Selectivity

Introduction: Eucaryotic cAMP-dependent protein kinase (cAK) exists as two different isozymes type I and II. In its deactivated status both types form a tetrameric complex consisting of two regulatory and two catalytic subunits. Each regulatory subunit offers two cooperative binding sites A and B for the allosteric activator cyclic AMP (cAMP). After binding of cAMP to the regulatory subunits the holoenzyme complex dissociates, releasing free catalytic subunits which then are able to phosphorylate suitable substrates.   

Chemically modified analogs of cAMP were shown to bind with different affinity to the A and B sites of the regulatory subunits (site selectivity) and in contrast to cAMP itself thus can discriminate between them. By combining appropriate couples of analogs only one of both cAK isozymes I or II can be activated preferably; giving hints which of both types is mainly responsible for the biological effect observed. It has been shown recently that cAK isozymes can act funtionally different and are not necessarily redundant. The fact of synergism gives strong evidence for a cAK- mediated biological effect, since for other cAMP receptors known so far (e.g. ion channels), this behavior is not possible. Decrease of the applicable concentration of analogs in cell culture experiments which in the case of expensive compounds is an economic benefit as well. As soon as the responsible cAK isozyme is identified, modulation of the corresponding signal pathway can be performed by more optimal agonists and antagonists designed to give maximal stimulation and inhibition, respectively, instead of high site selectivity.

 

Pairs of Analogs Suitable for Preferential Activation of cAK I / PKA I:

Analogue Pairs

BIOLOG 
Cat. No. 

Relative Affinity for cAK I

 

 

Relative Affinity for cAK II

Selectivity e
 cAK I / cAK II

References

A site 

 B site

 A site

 B site

 8-PIP-cAMP

P 002

2.3

0.065

 

 

0.046

3.2

  

    10 : 1

4, 6, 11, 12

 2-Cl-8-MA-cAMP

C 080

0.04

6.7

0.0095

0.72

4, 7

 

 

 8-PIP-cAMP

P 002

2.3

0.065

 

 

0.046

3.2

    5 : 1

4, 6, 11, 12

 8-HA-cAMP

H 006

0.033

1.8

0.086

0.87

 15

 

 

 6-MB-cAMP b

M 003

3.6

0.093

 

 

0.74

0.041

    5 : 1

4, 7

 8-AHA-cAMP

A 011

0.11

1.6

0.021

0.29

4, 6, 10

 8-PIP-cAMP

P 002

2.3

0.065

 

 

0.046

3.2

   5 : 1

4, 6, 10 -12

 8-AHA-cAMP

A 011

0.11

1.6

0.021

0.29

4, 6, 10

 6-MB-cAMP b

M 003

3.6

0.093

 

 

0.74

0.041

   2 : 1

4, 7

 8-HA-cAMP

H 006

0.033

1.8

0.086

0.87

15

 6-Bnz-cAMP

B 009

3.5

0.18

 

 

4.1

0.034

   2 : 1

4, 10, 11

 8-AHA-cAMP

A 011

0.11

1.6

0.021

0.29

4, 6, 10

 

 

The following pair of analogues results in potent stimulation of cAK I but is lacking isozyme selectivity. It can be used if only cAK I is present, if cAK II activation does not disturb or, of course, if both isozymes shall be activated:

 

 6-Phe-cAMP

P 006

18.0

0.48

 

40.0

0.44

1 : 4.3

4, 6, 14

 5,6-DCl-cBIMPc

D 011

0.11

5.1

0.38

42.0

5, 8

 

Pairs of Analogues Suitable for Preferential Activation of cAK II /PKA II:

The pairs shown were either already used successfully or are suggested due to their site selectivity data. Of course, other combinations can be formed, however, selectivity, metabolic stability as well as membrane permeability should be considered. Data are from references 4, 5, 8, 12 and are relative to cAMP (1.0 for all sites).

 


Analogue Pairs

BIOLOG 
Cat. No.

Relative Affinity for cAK I

 

Relative Affinity for cAK II

Selectivity e cAK I / cAK II

References

A site

 B site

 A site

B site

 6-MBC-cAMP

M 012

0.48

0.068

 

 

16.0

0.13

1 : 60

4, 14

 Sp-5,6-DCl-cBIMPS

D 014

0.022

0.13

0.034

14.0

5, 8, 13 - 16

 6-MBC-cAMP

M 012

0.48

0.068

 

 

16.0

0.13

1 : 33

4, 14

 Sp-8-Br-cAMPS

B 002

0.19

0.054

0.0033

2.2

5

 6-MBC-cAMP

M 012

0.48

0.068

 

 

16.0

0.13

1 : 18

4, 14

 8-PIP-cAMP

P 002

2.3

0.065

0.046

3.2

4, 6,11,12

 6-MBC-cAMP

M 012

0.48

0.068

 

 

16.0

0.13

1 : 13

4, 14

 Sp-8-PIP-cAMPS

P 005

0.098

0.0009

0.000005

0.33

12

 6-MBC-cAMP

M 012

0.48

0.068

 

 

16.0

0.13

1 : 9

4, 14

 8-Br-cAMP

B 007

1.3

1.0

0.11

6.8

5, 8

 6-Phe-cAMP

P 006

18.0

0.48

 

 

40.0

0.44

1 : 8

4, 6, 13, 14

 Sp-5,6-DCl-cBIMPS

D 014

0.022

0.13

0.034

14.0

5, 8, 13, 14

 6-Bnz-cAMP

B 009

3.5

0.18

 

4.1

0.034

1 : 6

4, 10, 11

 Sp-8-CPT-cAMPS

C 012

0.92

0.09

0.006

5.2

5, 11

 

 

The following pairs of analogues are combined to achieve maximal stimulation of cAK II, but are lacking isozyme selectivity. They should only be used if solely cAK II is present, if cAK I activation does not disturb or, of course, if both isozymes want to be activated:

 

 6-Phe-cAMP

P 006

18.0

0.48

 

40.0

0.44

1 : 5

4, 6, 14

 8-CPT-cAMP d

C 010

3.9

1.7

0.045

19.0

5, 8

 6-Phe-cAMP

P 006

18.0

0.48

 

 

40.0

0.44

1 : 4.3

4, 6, 14

 5,6-DCl-cBIMP c

D 011

0.11

5.1

0.38

42.0

5, 8

 


a) This analogue has only low membrane permeability.

b) N6-Monobutyryl- cAMP ( 6-MB-cAMP) is formed by metabolic degradation of dibutyryl-cAMP (Db-cAMP) releasing butyrate.

c) This analogue is not very resistant towards PDE hydrolysis. Addition of an unspecific PDE inhibitor such as IBMX is advisable here.

d) Caution: 8-CPT-cAMP is unselective and stimulates cGMP-dependent protein kinase as well.

e) Calculated by (A I x B I)½ : (A II x B II)½ . Actual selectivity should be higher due to synergism.

All compounds mentioned are offered by BIOLOG, for abbreviations please refer to our catalogue.

 

References:

1

Øgreid, D.; Døskeland, S.O.; Miller, J.P., J. Biol. Chem., 258, 1041 - 1049 (1983)

2

Robinson-Steiner, A. M.; Corbin, J. D., J. Biol. Chem., 258, 1032 - 1040 (1983)

3

Øgreid, D.; Ekanger, R.; Suva, R.H.; Miller, J.P.; Sturm, P.A.; Corbin, J.D.; Døskeland, S.O., Eur. J. Biochem.,150, 219 - 227 (1985)

4

Øgreid, D.; Ekanger, R.; Suva, R.H.; Miller, J.P.; Døskeland, S.O., Eur. J. Biochem., 181,19 - 31 (1989)

5

Dostmann, W.R.G.; Taylor, S.S.; Genieser, H.-G.; Jastorff, B.; Døskeland, S.O.; Øgreid, D., J. Biol. Chem., 265, 10484 - 10491(1990)

6

Steinberg, R.A.; Gorman, K.B.; Øgreid, D.; Døskeland, S.O.; Weber, I.T., J. Biol. Chem., 266, 3547 - 3553 (1991)

7

Otten, A.D.; Parenteau, L.A.; Døskeland, S.; McKnight, G.S., J. Biol. Chem., 266, 23074 - 23082 (1991)

8

Genieser, H.-G.; Winkler, E.; Butt, E.; Zorn, M.; Schulz, S.; Iwitzki, F.; Störmann, R.; Jastorff, B.; Døskeland, S.O.; Øgreid, D.; Ruchaud, S.; Lanotte, M., Carbohydr. Res., 234, 217 - 235 (1992)

9

Mira-y-Lopez, R.; Jaramillo, S.; Waxmann, S., J. Biol. Chem., 267, 23063 - 23068 (1992)

10

Skalhegg, B.S.; Landmark, B.F.; Døskeland, S.O.; Hansson, V.; Lea, T.; Jahnsen, T., J. Biol. Chem., 267,15707 - 15714 (1992)

11

Døskeland, S.O.; Maronde, E.; Gjertsen, B.T., Biochim. Biophys. Acta 1178, 249 - 258 (1993)

12

Øgreid, D.; Dostmann, W.; Genieser, H.-G.; Niemann, P.; Døskeland, S.O.; Jastorff, B., Eur. J. Biochem., 221, 1089 - 1094 (1994)

13

Maronde, E.; Middendorff, R.; Telgmann, R.; Müller, D.; Hemmings, B.; Tasken, K.; Olcese, J., J. Neurochem., 68, 770 - 777 (1997)

14

Maronde, E.; Wicht, H.; Tasken, K.; Genieser, H.G.; Olcese, J.; Korf, H.W., J. Pineal Res., 27, 170 - 182 (1999)

15

Schwede, F.; Christensen, A.; Liauw, S.; Hippe, T.; Kopperud, R.; Jastorff, B.; Døskeland, S. O., Biochemistry, 39, 8803 - 8812 (2000)

16

Kopperud, R.; Krakstad, C.; Selheim, F.; Døskeland, S.O., FEBS Lett., 546, 121 - 126 (2003)

 
Forgot your password?
Register
Username:
Password:
What is new!

February 10, 2012

PKG Inhibitor Peptide W45

W45 which can be used as a control peptide in applications of the peptide-based protein kinase G... [more...]

January 13, 2012

6-Fu-ATP-γ-S reference

Lo & Hollingsworth have successfully used 6-Fu-ATP-γ-S (Cat. No. F 008) from BIOLOG in... [more...]
Last modified: October 13, 2011